JSPR Jasper Therapeutics, Inc. - Class A Common Stock

NASDAQ · Biotechnology · View on SEC EDGAR ↗
$0.76
Price · Aug 19, 2026
Fundamentals as of May 14, 2026
52W Range
$0–$3
16% of range
Analyst Rating
BUY
11 analysts
Price Target
$9
+1106% upside
P/E (TTM)
-0.5
ROE
—
Net Profit Margin
—

JSPR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$0.76
Market Cap
—
P/E (TTM)
-0.5
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$0 – $3

JSPR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income —
EPS —
Free Cash Flow —
Margins —

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
JSPR
Peer Median
P/E (TTM)
-0.5
—

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
JSPR
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
JSPR
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
JSPR
Peer Median

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
JSPR
Peer Median

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
JSPR
Peer Median

JSPR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 11 analysts
  • Strong Buy 3 27.3%
  • Buy 5 45.5%
  • Hold 3 27.3%
  • Sell 0 0.0%
  • Strong Sell 0 0.0%

12-Month Price Target

3 analysts · 2026-08-16
Median target $6.00 +689.4%
Mean target $9.17 +1106.0%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
0.01%
Period EPS Actual EPS Est Surprise
March 31, 2026 $-0.04 $-0.50 0.46%
Dec. 31, 2025 $-0.32 $-0.76 0.44%
Sept. 30, 2025 $-1.25 $-1.24 -0.01%
June 30, 2025 $-1.74 $-1.35 -0.39%
March 31, 2025 $-1.41 $-1.34 -0.07%
Dec. 31, 2024 $-1.62 $-1.25 -0.36%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
JSPR — -0.5 — — — —
ABVC $53M -5.5 234.3% — -128.2% —
ACTU $142M -5.8 — — -843.5% —
LGVN — -0.4 -49.9% -1893.6% -247.7% 67.0%
ALLR $17M -0.0 — -3509.7% -102.1% —
NEUP $14M -30.9 — -2.4% -2.3% —
CELU $32M -0.3 -51.0% -345.4% 288.6% —
CLRB — -0.4 — — — —

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Balance Sheet 19
Annual Balance Sheet data for JSPR
Metric Trend 2025
Cash & Equivalents $29M
Prepaid Expense $6M
Other Current Assets $664.0K
Current Assets $35M
PP&E (Net) $102.0K
PP&E (Gross) $5M
Accum. Depreciation $5M
Other Non-current Assets $113.0K
Total Assets $36M
Accounts Payable $6M
Current Liabilities $13M
Other Non-current Liabilities $2M
Total Liabilities $32M
Common Stock $3.0K
Paid-in Capital $321M
Retained Earnings $-317M
Stockholders' Equity $4M
Liabilities + Equity $36M
Shares Outstanding 27,996,819
Per Share 1
Annual Per Share data for JSPR
Metric Trend 2025
EPS (TTM) $-3.95
Valuation (TTM) 4
Annual Valuation (TTM) data for JSPR
Metric Trend 2025
Revenue TTM $-119.0K
Net Income TTM $-76M
P/E -0.5
Earnings Yield -215.9%

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 53 filers · $8.5M total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
6 (-7 vs prior Q) 15 (+6 vs prior Q) 11 (-4 vs prior Q) 13 (-1 vs prior Q) -2.2M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
Qiming U.S. Ventures Management, LLC $2,210,934 928,964 25.94% Shares
Fernwood Investment Management, LLC $1,130,938 52,897 13.27% Shares
Velan Capital Investment Management LP $1,020,111 2,423,067 11.97% Shares
ACORN CAPITAL ADVISORS, LLC $604,027 1,438,159 7.09% Shares
KINGDON CAPITAL MANAGEMENT, L.L.C. $569,237 1,352,106 6.68% Shares
VANGUARD CAPITAL MANAGEMENT LLC $493,421 1,172,021 5.79% Shares
Rock Springs Capital Management LP $463,406 1,100,726 5.44% Shares
Carlyle Group Inc. $448,866 1,066,189 5.27% Shares
VANGUARD GROUP INC $274,396 149,943 3.22% Shares
MILLENNIUM MANAGEMENT LLC $204,999 486,933 2.41% Shares
Lion Point Capital, LP $195,765 465,000 2.30% Shares
Nuveen Asset Management, LLC $113,699 5,318 1.33% Shares
RENAISSANCE TECHNOLOGIES LLC $100,156 237,900 1.18% Shares
GEODE CAPITAL MANAGEMENT, LLC $89,234 211,903 1.05% Shares
CITADEL ADVISORS LLC $86,726 206,000 1.02% Call option
BlackRock, Inc. $71,413 169,627 0.84% Shares
VANGUARD FIDUCIARY TRUST CO $63,126 149,943 0.74% Shares
ADAR1 Capital Management, LLC $58,940 140,000 0.69% Shares
Quarry LP $55,374 131,529 0.65% Shares
JANE STREET GROUP, LLC $35,196 83,600 0.41% Call option
Jain Global LLC $21,549 51,185 0.25% Shares
JANE STREET GROUP, LLC $21,343 50,696 0.25% Shares
STATE STREET CORP $18,818 44,699 0.22% Shares
NORTHERN TRUST CORP $17,632 41,882 0.21% Shares
UBS Group AG $16,172 38,414 0.19% Shares
DIKER MANAGEMENT LLC $15,000 35,000 0.18% Shares
Qube Research & Technologies Ltd $14,197 33,722 0.17% Shares
XTX Topco Ltd $14,064 33,406 0.17% Shares
Rehmann Capital Advisory Group $13,405 15,300 0.16% Shares
SIMPLEX TRADING, LLC $12,036 28,591 0.14% Shares
Ikarian Capital, LLC $10,144 24,093 0.12% Shares
CITADEL ADVISORS LLC $9,430 22,400 0.11% Put option
GROUP ONE TRADING LLC $8,391 19,930 0.10% Shares
Sequent Planning LLC $6,273 14,900 0.07% Shares
BANK OF AMERICA CORP /DE/ $5,975 14,192 0.07% Shares
IEQ CAPITAL, LLC $5,699 13,538 0.07% Shares
Engineers Gate Manager LP $5,468 12,989 0.06% Shares
LPL Financial LLC $5,157 12,250 0.06% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $4,326 10,300 0.05% Put option
Tower Research Capital LLC (TRC) $3,930 9,336 0.05% Shares
OSAIC HOLDINGS, INC. $2,100 5,000 0.02% Shares
Arax Advisory Partners $241 573 0.00% Shares
GSA CAPITAL PARTNERS LLP $225 534,697 0.00% Shares
MORGAN STANLEY $84 200 0.00% Shares
FEDERATED HERMES, INC. $80 189 0.00% Shares
NATIONAL BANK OF CANADA /FI/ $63 160 0.00% Shares
BNP PARIBAS FINANCIAL MARKETS $59 141 0.00% Shares
SBI Securities Co., Ltd. $27 64 0.00% Shares
JONES FINANCIAL COMPANIES LLLP $17 50 0.00% Shares
JPMORGAN CHASE & CO $4 9 0.00% Shares
SG Americas Securities, LLC $4 10,556 0.00% Shares
ROYAL BANK OF CANADA $0 40 0.00% Shares
Caitong International Asset Management Co., Ltd $0 1 0.00% Shares

Company insiders 22 insiders · 6 officers · 13 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Jeetinder Singh Mahal CEO and President Feb. 6, 2026 A 25,009 0 0 $0
Ron Martell President, CEO and Director Jan. 2, 2026 A 74,118 1 0 $99,630
Herb Cross Chief Financial Officer Jan. 2, 2026 A — 0 0 $0
Matthew E Ros Chief Operating Officer July 20, 2026 P — 0 0 $0
Edwin Jonathan Tucker Chief Medical Officer June 4, 2025 A 400 0 0 $0
Kevin N. Heller Executive Vice President, Research and Development March 21, 2022 A — 0 0 $0
Patrick J Crutcher Director July 20, 2026 P — 0 0 $0
Judith Anne Shizuru Director Sept. 22, 2025 P 156,901 1 0 $99,630
Svetlana Lucas Director Sept. 22, 2025 P 20,000 1 0 $48,600
Thomas G Wiggans Director Sept. 22, 2025 P 41,000 1 0 $99,630
Scott C. Brun Director July 3, 2025 A — 0 0 $0
Kapoor Vishal Director July 3, 2025 A — 0 0 $0
Chris Nolet Director July 3, 2025 A 32,500 0 0 $0
Kurt Von Emster Director July 3, 2025 A 21,175 0 0 $0
Anna Louise French Director June 6, 2024 A 23,750 0 0 $0
William Lis Director Oct. 13, 2023 S 53,521 0 0 $0
Lawrence Otto Klein Director June 7, 2023 A 24,500 0 0 $0
Abingworth LLP 10% owner March 21, 2022 A — 0 0 $0
Amplitude Healthcare Holdings LLC 10% owner Sept. 24, 2021 M 2,300,000 0 0 $0
Kenneth F Clifford — Sept. 24, 2021 M 2,300,000 0 0 $0
Howard I Hoffen — Sept. 24, 2021 M 2,300,000 0 0 $0
VENKATARAMAN BALAJI — Sept. 24, 2021 M 2,300,000 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 2 positions

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Velan Capital Master Fund LP, Velan Capital Holdings LLC, Velan Horizon Fund LP, Velan Horizon GP LLC, Avego Healthcare Capital, L.P., Avego Healthcare Capital Holdings, LLC, Avego Management LLC, Velan Capital Investment Management LP, Velan Capital Management LLC, Morgan Adam, VENKATARAMAN BALAJI, Kapoor Vishal ×4 filings July 20, 2026 9.88% Amendment M&A / sale SEC
Abingworth LLP, Abingworth Bioventures VII, LP Oct. 4, 2021 — Initial filing Passive investment SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF ownership Held by 2 ETFs

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
VXF · VANGUARD INDEX FUNDS — — July 15, 2026 Daily
VTI · VANGUARD INDEX FUNDS — — July 15, 2026 Daily